Cargando…

Optic Pit Maculopathy: Adjunctive Treatment Using Oral Spironolactone and Topical Dorzolamide

PURPOSE: There is no consensus for the treatment of optic disc pit maculopathy (ODPM). We describe a case of ODPM refractory to vitrectomy that was successfully treated with systemic spironolactone and topical dorzolamide 2%. METHODS: Case report. RESULTS: A 27-year-old male was referred for decreas...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Susan Ruyu, You, Eunice, Hebert, Melanie, Dirani, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165556/
https://www.ncbi.nlm.nih.gov/pubmed/34079390
http://dx.doi.org/10.2147/IMCRJ.S307057
_version_ 1783701347055435776
author Qi, Susan Ruyu
You, Eunice
Hebert, Melanie
Dirani, Ali
author_facet Qi, Susan Ruyu
You, Eunice
Hebert, Melanie
Dirani, Ali
author_sort Qi, Susan Ruyu
collection PubMed
description PURPOSE: There is no consensus for the treatment of optic disc pit maculopathy (ODPM). We describe a case of ODPM refractory to vitrectomy that was successfully treated with systemic spironolactone and topical dorzolamide 2%. METHODS: Case report. RESULTS: A 27-year-old male was referred for decreased vision in the right eye secondary to macular edema. Fundus examination and optical coherence tomography imaging revealed an optic pit maculopathy with significant macular schisis and intraretinal fluid. After an initial observation period, we performed pars plana vitrectomy with internal limiting membrane peeling, fibrin glue, and gas endotamponade. At the 2 months postoperative follow-up, anatomic and functional outcomes remained unimproved. Oral spironolactone and topical dorzolamide 2% were, therefore, added. Significant reduction in the intraretinal fluid and macular schisis was demonstrated at the last follow-up 2 years postoperative. CONCLUSION: The mechanisms underlying optic disc pit maculopathy remain controversial, and treatment guidelines are unclear. To our knowledge, this is the first description of an OPDM treated with a combination systemic mineralocorticoid receptor antagonist and topical carbonic anhydrase inhibitor as adjuvant therapy to vitrectomy with favorable outcomes. We also review the literature and propose mechanisms through which these treatment entities may act.
format Online
Article
Text
id pubmed-8165556
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-81655562021-06-01 Optic Pit Maculopathy: Adjunctive Treatment Using Oral Spironolactone and Topical Dorzolamide Qi, Susan Ruyu You, Eunice Hebert, Melanie Dirani, Ali Int Med Case Rep J Case Report PURPOSE: There is no consensus for the treatment of optic disc pit maculopathy (ODPM). We describe a case of ODPM refractory to vitrectomy that was successfully treated with systemic spironolactone and topical dorzolamide 2%. METHODS: Case report. RESULTS: A 27-year-old male was referred for decreased vision in the right eye secondary to macular edema. Fundus examination and optical coherence tomography imaging revealed an optic pit maculopathy with significant macular schisis and intraretinal fluid. After an initial observation period, we performed pars plana vitrectomy with internal limiting membrane peeling, fibrin glue, and gas endotamponade. At the 2 months postoperative follow-up, anatomic and functional outcomes remained unimproved. Oral spironolactone and topical dorzolamide 2% were, therefore, added. Significant reduction in the intraretinal fluid and macular schisis was demonstrated at the last follow-up 2 years postoperative. CONCLUSION: The mechanisms underlying optic disc pit maculopathy remain controversial, and treatment guidelines are unclear. To our knowledge, this is the first description of an OPDM treated with a combination systemic mineralocorticoid receptor antagonist and topical carbonic anhydrase inhibitor as adjuvant therapy to vitrectomy with favorable outcomes. We also review the literature and propose mechanisms through which these treatment entities may act. Dove 2021-05-26 /pmc/articles/PMC8165556/ /pubmed/34079390 http://dx.doi.org/10.2147/IMCRJ.S307057 Text en © 2021 Qi et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Qi, Susan Ruyu
You, Eunice
Hebert, Melanie
Dirani, Ali
Optic Pit Maculopathy: Adjunctive Treatment Using Oral Spironolactone and Topical Dorzolamide
title Optic Pit Maculopathy: Adjunctive Treatment Using Oral Spironolactone and Topical Dorzolamide
title_full Optic Pit Maculopathy: Adjunctive Treatment Using Oral Spironolactone and Topical Dorzolamide
title_fullStr Optic Pit Maculopathy: Adjunctive Treatment Using Oral Spironolactone and Topical Dorzolamide
title_full_unstemmed Optic Pit Maculopathy: Adjunctive Treatment Using Oral Spironolactone and Topical Dorzolamide
title_short Optic Pit Maculopathy: Adjunctive Treatment Using Oral Spironolactone and Topical Dorzolamide
title_sort optic pit maculopathy: adjunctive treatment using oral spironolactone and topical dorzolamide
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165556/
https://www.ncbi.nlm.nih.gov/pubmed/34079390
http://dx.doi.org/10.2147/IMCRJ.S307057
work_keys_str_mv AT qisusanruyu opticpitmaculopathyadjunctivetreatmentusingoralspironolactoneandtopicaldorzolamide
AT youeunice opticpitmaculopathyadjunctivetreatmentusingoralspironolactoneandtopicaldorzolamide
AT hebertmelanie opticpitmaculopathyadjunctivetreatmentusingoralspironolactoneandtopicaldorzolamide
AT diraniali opticpitmaculopathyadjunctivetreatmentusingoralspironolactoneandtopicaldorzolamide